Business Context and Reporting Period
Company: Stryker Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended September 30, 2007
Business Overview: Stryker is a leading medical technology company with two primary reportable segments: Orthopaedic Implants and MedSurg Equipment. The company sells implants, surgical equipment, and navigation systems globally. Domestic sales accounted for 64% of total revenues in the first nine months of 2007.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2006 |
|---|---|---|---|
| Net Sales | $1,453.2 | $4,342.4 | $3,746.8 |
| Gross Profit | $996.2 | $3,001.7 | $2,574.7 |
| Gross Margin | 68.6% | 69.1% | 68.7% |
| Operating Income | $307.3 | $944.4 | $759.8 |
| Net Earnings (Continuing Ops) | $228.7 | $710.6 | $544.7 |
| Net Earnings (Total) | $228.7 | $741.3 | $549.8 |
| Diluted EPS (Continuing Ops) | $0.55 | $1.70 | $1.32 |
| Cash from Operations | $297.2 | $660.8 | $496.9 |
| Cash & Equivalents | $170.9 | $170.9 | $416.6 (Dec 31, 2006) |
| Marketable Securities | $1,902.5 | $1,902.5 | $998.2 (Dec 31, 2006) |
| Outstanding Borrowings | $17.4 | $17.4 | $14.8 (Dec 31, 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18% in the third quarter and 16% for the nine months ended September 30, 2007, compared to the prior year. Growth was driven by increased unit volume and product mix, with a 2% favorable impact from foreign currency exchange rates.
- Profitability: Net earnings from continuing operations rose 22% in the quarter and 30% for the nine-month period. Operating margins improved slightly due to manufacturing efficiencies and lower royalty costs in 2006.
- Discontinued Operations: The company completed the sale of its outpatient physical therapy business (Physiotherapy Associates) in June 2007, resulting in a $25.7 million net gain on sale recorded in the second quarter. This business is now classified as discontinued operations.
- Impairment Charges: A $19.8 million intangible asset impairment charge was recorded in the second quarter of 2007 related to intervertebral body fusion cage patents following an FDA downgrade. This contrasts with a $52.7 million purchased in-process research and development charge in the first quarter of 2006 related to the Sightline acquisition.
- Liquidity: Working capital increased to $3,352.0 million from $2,182.8 million at year-end 2006. Cash and cash equivalents decreased to $170.9 million, while marketable securities increased significantly to $1,902.5 million.
Guidance, Outlook, and Risks
Outlook and Guidance
- 2007 EPS Projection: Management projects diluted net earnings per share from continuing operations for 2007 to approximate $2.37, a 27% increase over 2006. Adjusted diluted EPS (excluding impairment and R&D charges) is projected at $2.40.
- Sales Growth: The company forecasts constant currency net sales growth for 2007 in the range of 13.0% to 13.5%, an increase from the previous forecast of 12% to 13%.
- Currency Impact: If exchange rates hold near September 30, 2007 levels, the company anticipates a favorable impact on net sales of approximately 2.5% to 3.0% in the fourth quarter.
Risks and Contingencies
- Legal Proceedings:
- DOJ Investigation: Reached a non-prosecution agreement in September 2007 regarding an investigation into consulting contracts with orthopedic surgeons. The agreement requires compliance with specific standards for 18 months.
- Antitrust Inquiry: The DOJ Antitrust Division is investigating possible violations of federal criminal law regarding orthopaedic implant devices (subpoena issued June 2006).
- SEC Inquiry: The SEC made an informal inquiry in October 2007 regarding possible violations of the Foreign Corrupt Practices Act in foreign countries.
- Regulatory Risks: Potential delays in FDA approvals for new products (e.g., OP-1, FlexiCore, CerviCore) and regulatory actions affecting product classification.
- Market Risks: Pricing pressures, cost-containment measures by payors, and changes in foreign exchange markets.
Investor Verification Checklist
- Legal Resolution Status: Verify the specific compliance requirements and potential financial penalties associated with the non-prosecution agreement with the U.S. Attorney's office in Newark.
- Antitrust and FCPA Inquiries: Monitor updates on the DOJ Antitrust investigation and the SEC inquiry regarding the Foreign Corrupt Practices Act, as outcomes could result in significant fines or operational restrictions.
- Product Launch Execution: Confirm the timeline and commercial success of new product launches (e.g., Sightline flexible endoscopes, OP-1 applications) which are critical to meeting the raised sales guidance.
- Inventory Levels: Review the increase in days sales in inventory (155 days vs. 138 days at year-end 2006) to ensure it aligns with anticipated demand and does not signal future write-downs.
- Foreign Currency Exposure: Assess the sensitivity of future earnings to fluctuations in foreign exchange rates, given that 36% of revenue is international and the outlook assumes favorable rates.